BCYC - Bicycle Therapeutics: Early Stage Platform Technology Play With Multiple Upside Drivers

*This article was originally published for ROTY subscribers on Jan. 24th, but has been updated where necessary. Despite the recent rebound, the story remains in early innings with substantial upside potential ahead should internal efforts in oncology and/or partnered projects continue to deliver promising data.

Shares of UK-based biotech firm Bicycle Therapeutics (BCYC) have risen by 22% since I called the stock a Speculative Buy this past September, noting that proof of concept for this unique platform technology player had recently been established via a partnered program. Shares are still trading a